494 related articles for article (PubMed ID: 28720158)
1. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
[TBL] [Abstract][Full Text] [Related]
2. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
[TBL] [Abstract][Full Text] [Related]
3. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
[TBL] [Abstract][Full Text] [Related]
4. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
[TBL] [Abstract][Full Text] [Related]
5. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
[TBL] [Abstract][Full Text] [Related]
6. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
[TBL] [Abstract][Full Text] [Related]
7. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
[TBL] [Abstract][Full Text] [Related]
9. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
[TBL] [Abstract][Full Text] [Related]
10. Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.
Darbà J; Kaskens L; Lacey L
Eur J Health Econ; 2015 Nov; 16(8):895-905. PubMed ID: 25348897
[TBL] [Abstract][Full Text] [Related]
11. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
12. What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.
Reed C; Happich M; Argimon JM; Haro JM; Wimo A; Bruno G; Dodel R; Jones RW; Vellas B; Belger M
J Alzheimers Dis; 2017; 57(3):797-812. PubMed ID: 28304285
[TBL] [Abstract][Full Text] [Related]
13. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
[TBL] [Abstract][Full Text] [Related]
14. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain.
Lopez-Bastida J; Serrano-Aguilar P; Perestelo-Perez L; Oliva-Moreno J
Neurology; 2006 Dec; 67(12):2186-91. PubMed ID: 17190942
[TBL] [Abstract][Full Text] [Related]
15. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.
Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jönsson L
Int Psychogeriatr; 2011 Feb; 23(1):73-85. PubMed ID: 20619068
[TBL] [Abstract][Full Text] [Related]
16. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.
Tahami Monfared AA; Khachatryan A; Hummel N; Kopiec A; Martinez M; Zhang R; Zhang Q
J Alzheimers Dis; 2024; 99(1):191-206. PubMed ID: 38640156
[TBL] [Abstract][Full Text] [Related]
17. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
[TBL] [Abstract][Full Text] [Related]
18. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
[TBL] [Abstract][Full Text] [Related]
19. Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours.
Haro JM; Kahle-Wrobleski K; Bruno G; Belger M; Dell'Agnello G; Dodel R; Jones RW; Reed CC; Vellas B; Wimo A; Argimon JM
J Nutr Health Aging; 2014 Jul; 18(7):677-84. PubMed ID: 25226106
[TBL] [Abstract][Full Text] [Related]
20. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.
Belger M; Haro JM; Reed C; Happich M; Kahle-Wrobleski K; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
BMC Med Res Methodol; 2016 Jul; 16():83. PubMed ID: 27430559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
